Global Blood Glucose Monitoring System Market

MARKET SCOPE:

The global blood glucose monitoring system market is projected to grow significantly, registering a CAGR of 6.1% during the forecast period (2025 – 2034).

The blood glucose monitoring system market is mainly being driven by the growing prevalence of diabetes globally due to a sedentary lifestyle, unhealthy diet and aging population. As individuals became increasingly aware of the importance of regularly monitoring their blood glucose levels for the effective management of diabetes, the adoption of blood glucose monitoring systems began to surge. The introduction of new technologies such as continuous glucose monitoring (CGM) devices and glucometers connected to smart devices improved accuracy and convenience for patients, resulting in a significant increase in patient compliance which contributed to market growth. This growth is supported by government and healthcare initiatives that advocate for early diagnosis and monitoring of diabetes.

Also, one of the main drivers is the shift towards minimally invasive glucose monitoring options and consumer preferences moving towards non-invasive glucose monitoring systems. Furthermore, with artificial intelligence and data analytics integrated into monitoring systems, heavy personalization workflows and the ability to monitor in real-time positively affect patient outcomes, reducing long-term complications. Increased demand for home healthcare devices, higher healthcare spending and favorable reimbursement programs in developed regions are further sustained adoption behaviour. All these driving forces foster a strong market ecosystem for both established companies and new entrants to sustain growth during the forecast period.

MARKET OVERVIEW:

Driver: Rising Prevalence of Diabetes Driving Demand for Monitoring Systems

The increasing prevalence of diabetes worldwide is a major driver for the blood glucose monitoring system market. The International Diabetes Federation (IDF) states that the number of diabetes cases will see an increase worldwide from lifestyle choices (i.e., food choices, obesity, lack of activity, and aging). Sustained blood glucose monitoring has important implications for disease management, allowing patients to be aware of blood glucose changes, preventing complications, and facilitating use of the most suitable treatment.

Nonetheless, innovations such as continuous glucose monitoring (CGM) devices or glucometers connected to smartphones, make monitoring easier and much more convenient for patients and offer greater accuracy. Other initiatives government or even health care organizations are developing include early diagnosing and monitoring programs that focus on minimizing care associated with patients who have diabetes. Therefore, there is slight uptick in monitoring devices across both developing and developed countries.

Restraint: High Costs of Advanced Devices Limiting Adoption

One of the main hindering factors for the market, is the high cost associated with sophisticated blood glucose monitoring systems, mainly continuous blood glucose monitoring devices and insulin pump integrations. Although basic glucometers are quite affordable, the repeated cost for consumables (e.g., test strips, sensors, transmitters) can often add up to a significant amount of money for the patient, particularly in low-, and middle-income countries. Limited reimbursement coverage in some regions also lowers accessibility and means that many diabetic patients are unable to justify using the system despite its clear long-term advantages. This cost factor means that it limits the ability for penetration of advanced technology, especially in segments with low healthcare spend and significantly hampers growth for the overall market.

Opportunity: Technological Advancements in Non-Invasive and Connected Devices

The progress of non-invasive and minimally invasive monitoring modalities is a tremendous opportunity to grow the market. New innovations such as wearable sensors, optical spectroscopy-based monitors, and smart contact lenses, have completely changed the way patients monitor their glucose blood levels without repeatedly pricking their fingers, increasing overall comfort and compliance with home glucose monitoring.

Furthermore, the use of AI capability, mobile applications and cloud-based platforms allow real-time performance tracking, remote consultations, and personalized insights to track treatment options. These developments support a shift towards connected healthcare ecosystems while simultaneously improving the outcomes for patients living with chronic diseases. A company that invests in a user-friendly, affordable, and connected solution, is most likely going to benefit and be able to capture a larger share of this rapidly expanding market.

SEGMENTATION ANALYSIS:

The Invasive Segment is anticipated to grow significantly during the forecast period

The invasive segment of the blood glucose monitoring system market is expected to remain dominant through the forecast period due to ubiquitous adoption and clinically demonstrated reliability. Devices like self-monitoring blood glucose (SMBG) systems (along with a range of continuous glucose monitoring or CGM devices) are predominantly used for the management of both type 1 and type 2 diabetes. Their well-documented accuracy, availability of consumables like test strips and sensors, and overwhelming advocacy by clinical professionals support this high use. Furthermore, favorable reimbursement policies in developed regions and lower relative cost compared to emerging alternatives will continue to bolster this segment’s growth and keep it as the leading contributor to revenue.

REGIONAL ANALYSIS:

The North America region is set to witness significant growth during the forecast period

The North America blood glucose monitoring system market is expected to remain the dominant region during the forecast period, driven by the high diabetes prevalence, supported by the advanced healthcare structures and acceptance of newly developed techniques for monitoring blood glucose levels like continuous glucose monitoring (CGM) devices that will support continual use of glucose monitoring. The United States will hold a major share in the market during the forecast period by having favorable reimbursement structure for blood glucose devices, along with increasing spending in health care by both private and public health agencies, and there are major manufacturers of medical devices. Furthermore, patients are becoming increasingly aware of diabetes and proper management. The shift towards digital health and smartphone-connected devices have made wireless monitoring easier and promoted use of other devices to increase water and/or fluid intake. The prevalence of lifestyle choices that increases risk of diabetes like obesity, as well as increased proportion of aging/potentially diabetic populations will continue to drive the need for reliable glucose monitoring systems.

In Contrast, the Asia Pacific blood glucose monitoring system market will be the fastest growing region by volume, given its rapid increase in diabetic population, especially countries such as India, China, and Japan. Increased healthcare spending and government awareness campaigns, in addition to the availability of inexpensive public-recognized monitoring options will only continue to help in their adoption rate. The availability of local manufacturers selling cheap devices will allow the urban and rural public to access advanced technologies at their disposal. Furthermore, the increasing emphasis on preventive healthcare and move to home-based monitoring will continue to grow in this region. With ongoing vision and innovations in technology and healthcare evolution, Asia Pacific will expand its market share considerably over the next several years.

COMPETITIVE ANALYSIS:

The global blood glucose monitoring system market is reasonably competitive with mergers, acquisitions, and Product launches. See some of the major key players in the market.

Senseonics

Nipro Corp

Terumo Corporation

LifeScan IP Holdings, LLC

Dexcom, Inc

Ascensia Diabetes Care Holdings AG

Medtronic

Abbott

Braun SE

Hoffmann-La Roche Ltd

Recent Development:

In September 2024, Senseonics received FDA clearance for Eversense 365, the world’s first 365-day implantable continuous glucose monitoring (CGM) system, and launched it commercially in October 2024 through its partner Ascensia.

In March 2024, Dexcom received FDA approval for the G7 15-Day CGM sensor, extending wear duration and improving accuracy with a MARD of ~8%.

In January 2024, Abbott continues to expand its FreeStyle Libre CGM platform, with earlier partnerships integrating its technology into insulin delivery systems with Tandem and Sanofi, though no major new device launch was announced in the past year.

SCOPE OF THE REPORT:

By Type

• Non-invasive
• Invasive

By Patient Type

• Type-1 Diabetes
• Type-2 Diabetes

By Device Type

• Continuous Glucose Monitoring Systems
• Sensors
• Transmitters & Receivers
• Self-Monitoring Blood Glucose Systems
• Blood Glucose Meters
• Test Strips
• Lancets

By Modality

• Wearable
• Non-wearable

By Distribution Channel

• Institutional Sales
• Retail Sales

By Region

• North America (United States & Canada)
• Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea, Australia and Rest of Asia-Pacific)
• Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa and Rest of Middle East and Africa)

KEY REASONS TO PURCHASE THIS REPORT:

It provides a technological development map over time to understand the industry’s growth rate and indicates how the blood glucose monitoring system market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which blood glucose monitoring system submarket will be the main driver of the overall market from 2025 to 2034.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2034 and which country will lead the market in 2034. Show more